AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2004 AUG 5 - (NewsRx.com & NewsRx.net) -- Sequenom, Inc., (SQNM) announced that through a collaboration with an international consortium led by The Chinese University of Hong Kong (CUHK) and Boston University (BU) a novel process to determine genetic mutations in circulating fetal nucleic acids in maternal plasma has been developed.
This process is published in an article released in the online Early Edition of the Proceedings of the National Academy of Sciences.
Investigators, led by Rossa W.K. Chiu, MD, PhD, FRCPA, of CUHK and Chunming Ding, PhD of BU, used MassARRAY technology to detect the inheritance of the four most common Southeast Asian beta-thalassemia mutations in at-risk pregnancies between 7-to-21 weeks of gestation and to analyze fetal haplotypes based on a genetic variation linked to the beta-globin locus HBB.
"Utilizing the superior sensitivity and specificity of the MassARRAY system, we have been able to isolate certain fetal point mutations and haplotypes in a non-invasive procedure with no risk to the fetus," said Charles R. Cantor, PhD, Sequenom's chief scientific officer.
"Sequenom's ability to perform trace DNA analysis has enabled us to analyze circulating fetal DNA, a goal that on a large scale has been difficult in the past using other techniques due to their dependence on the fractional concentration of the circulating DNA and their lack of sensitivity.
"The MassARRAY system, however, is able to detect and analyze small amounts of DNA, even against the large background of maternal DNA.
...
Source: HighBeam Research, MassARRAY system detects fetal genetic mutations in maternal plasma.